PMID- 34094914
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell 
      Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report.
PG  - 633446
LID - 10.3389/fonc.2021.633446 [doi]
LID - 633446
AB  - Immunotherapy alone or chemo-immunotherapy has recently been recommended for 
      treating advanced lung carcinoma in patients without driver mutations. However, 
      the efficacy of immunotherapy and molecular mechanism in large-cell lung cancer 
      (LCLC) remains unclear. Here, we reported a rare case of multiple fulminant 
      postoperative body and mouth metastases in LCLC treating with combination 
      immunotherapy. Initially, the patient was diagnosed as early stage LCLC and 
      underwent a radical resection of the right lower lobe. Just one month later, 
      multiple fulminant body and mouth lesions appeared in the right upper arm, right 
      elbow, right waist, and tongue root. Meanwhile, serum neuron specific enolase 
      (NSE) concentration dramatically increased from 12.12 to 30.14 ng/ml. 
      Immumohistochemistry findings demonstrated moderate PD-L1 expressions with tumor 
      proportion score (TPS), while next-generation sequencing indicated moderate tumor 
      mutational burden (TMB) levels and gene mutations in PBRM1 L1230P and TP53 L194R 
      of both foci. Besides, loss of heterozygosity (LOH) at human leukocyte antigen 
      (HLA) class I (HLA-A*02:03, HLA-B*55:02 and HLA-C*12:03) were detected in the 
      right upper arm metastasis, which may facilitate malignant postoperative 
      metastases in this case. Notably, this patient received combination therapy with 
      anti-PD-1 antibody sintilimab plus anlotinib, and achieved a partial response for 
      at least 12 months. Using an integrated computational method, the mutant peptide 
      TEIPENDIPL derived from PBRM1 L1230P was predicted to be a specific neoantigen 
      and could still be presented by HLA-B*40:01. This case suggests that 
      immunotherapy plus antiangiogenic drug may provide an alternative therapeutic 
      option for advanced LCLC patients without common gene mutations.
CI  - Copyright (c) 2021 Luo, Zhang, Xiao, Wang, Zhang, Huang, Cao, Sun, Zhao, Lin, Wu 
      and Wang.
FAU - Luo, Zhilin
AU  - Luo Z
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Xiao, Yajie
AU  - Xiao Y
AD  - Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.
FAU - Wang, Rui
AU  - Wang R
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Zhang, Liping
AU  - Zhang L
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Huang, Chenglu
AU  - Huang C
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Cao, Yu
AU  - Cao Y
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Sun, Chao
AU  - Sun C
AD  - Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.
FAU - Zhao, Yongtian
AU  - Zhao Y
AD  - Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.
FAU - Lin, Hanqing
AU  - Lin H
AD  - Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.
FAU - Wu, Dongfang
AU  - Wu D
AD  - Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.
FAU - Wang, Tianhu
AU  - Wang T
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
LA  - eng
PT  - Case Reports
DEP - 20210520
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8173040
OTO - NOTNLM
OT  - antiangiogenic drugs
OT  - immunotherapy
OT  - large-cell lung carcinoma
OT  - loss of heterozygosity at HLA
OT  - multiple postoperative metastases
COIS- YX, CS, YZ, HL and DW were employed by YuceBio Technology Co. Ltd. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/01/01
CRDT- 2021/06/07 06:03
PHST- 2020/11/25 00:00 [received]
PHST- 2021/04/19 00:00 [accepted]
PHST- 2021/06/07 06:03 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.633446 [doi]
PST - epublish
SO  - Front Oncol. 2021 May 20;11:633446. doi: 10.3389/fonc.2021.633446. eCollection 
      2021.